Sai Life Sciences (SAILIFE) Q2 25/26 earnings summary

Executive summary

• Delivered a strong Q2 FY26 with robust demand and positive momentum across discovery, development, and manufacturing services, driven by global client trust, scientific execution, and expanding client relationships.

• Investments in new modalities, advanced technologies, and capacity expansion are strengthening long-term competitiveness and scientific capabilities.

• Successfully offset biotech funding slowdown with increased engagement from large pharma clients and expanded early-stage development projects.

• Entered the animal health segment with a dedicated veterinary API facility and established partnerships with top global animal health companies.

• Board approved unaudited standalone and consolidated financial results for the quarter and six months ended 30 September 2025, with statutory auditor review and unmodified conclusion.

Financial highlights

• H1 FY26 revenue reached ₹10,338.89 million (INR 1,034 crore), up 53% year-over-year from ₹6,752.85 million in H1 FY25.

• Q2 FY26 revenue was ₹5,374.70 million (₹537 Cr), up 36% year-over-year; EBITDA for H1 FY26 was ₹281 crore, up 101% year-over-year.

• PAT for Q2 FY26 stood at ₹838.44 million (₹84 Cr), up 102% year-over-year; H1 FY26 PAT was ₹1,442.99 million.

• EBITDA margin for H1 FY26 improved to 27.2%, up 652 bps year-over-year.

• CapEx for H1 FY26 was ₹248 crore, focused on R&D infrastructure and new modalities.

Outlook and guidance

• Capacity expansion on track to increase installed capacity from 700 KL to 1,150 KL by end of FY27.

• Positioned to achieve 15%-20% revenue CAGR over 3–5 years and 28%-30% EBITDA margins in the next 2–3 years.

• Focus remains on improving asset productivity, optimizing working capital, and strengthening margin profile.

• Management and auditors confirm compliance with accounting standards and regulatory requirements, with no material misstatements identified.